The Main Therapeutic Targets for Crohn Disease and Ulcerative Colitis

Abstract

Inflammatory bowel diseases -Crohn's disease and ulcerative colitisare an extremely urgent problem both in Russia and around the world. A serious obstacle is the objective difficulties in the treatment of such patients due to the characteristics of the diseases themselves, due to the complexity of pathogenesis. To date, the most successful methods of pathogenetic therapy are anticytokines and the use of drugs aimed at suppressing the T-cell response. At the same time, although the arsenal of pathogenetic drugs for patients with inflammatory bowel diseases has been significantly expanded in recent years, there is an objective need to develop new therapy options, which is associated with insufficiently satisfactory treatment results for these patients. This publication is a literature review on the main targeted areas of therapy for these diseases in modern conditions -the advantages and disadvantages of individual pathogenetic approaches in the treatment of ulcerative colitis and Crohn's disease. The article discusses such approaches as anticytokine therapy, blockade of the a4b7 subunit of lymphocytes, the effect on the endothelial adhesion molecule MAdCAM-1, the use of Janus kinase inhibitors, blockade of sphingosine-1-phosphate receptors. The advantages and disadvantages of these methods are given.